Please login to the form below

Not currently logged in
Email:
Password:

Silence appoints chief medical officer

Expands role of chief medical adviser Dr Michael Khan

Silence Therapeutics, Michael KhanUK biotech Silence Therapeutics has appointed Dr Michael Khan as its chief medical officer, four months after he joined the company as chief medical adviser.

In his new role Dr Khan, who is an associate professor of medicine at the University of Warwick, will oversee the company's 2013 programme of phase II clinical trials.

These studies involve Silence's investigational portfolio of RNA interference (RNAi) therapeutics, which aim to treat conditions by selectively turning off genes expressed in an individual with a certain disease.

Silence has several of these therapies in development across several indications, and is involved in several partnerships with companies including AstraZeneca.

Dr Khan said: “These are very exciting times for Silence Therapeutics, with one oncology drug advancing to phase II. Moreover, with a range of new indications in the pipeline, I am really happy to be a part of this dynamic new enterprise.”

Dr Khan's work has covered cancer and diabetes, and he has written several books on the subjects. He also teaches postgraduates and undergraduates in medicine and biological sciences in these areas.

In addition, Dr Khan is a fellow of the Royal College of Physicians of London and a member of the Association of Physicians, HEART-UK and Diabetes UK.

3rd January 2013

From: Research

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Research Partnership

We are the largest independent healthcare market research and consulting agencies in the world. Trusted partner to the global pharmaceutical...

Latest intelligence

Brain power: fresh approaches to Alzheimer’s drug discovery
New alliances are learning from past mistakes and breaking down research barriers...
Genomics integration: can the NHS rise to the challenge?
Experts gather to discuss the UK’s genomic landscape...
London
“Brexit has been a catalyst for UK clinical research... it’s turbocharged change”
The UK clinical trials environment has been transformed in recent years – but can it really buck Brexit’s risks and uncertainties?...

Infographics